首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Carvedilol a cardiovascular drug prevents vascular smooth muscle cell proliferation migration and neointimal formation following vascular injury.
【2h】

Carvedilol a cardiovascular drug prevents vascular smooth muscle cell proliferation migration and neointimal formation following vascular injury.

机译:卡维地洛是一种心血管药物可防止血管损伤后血管平滑肌细胞增殖迁移和新内膜形成。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Carvedilol is a cardiovascular drug currently used for the treatment of hypertension. Clinical studies have recently demonstrated efficacy in angina and congestive heart failure. Recently, carvedilol has been shown to attenuate oxygen free radical-initiated lipid peroxidation and to inhibit vascular smooth muscle mitogenesis induced by a wide variety of growth factors. These findings are of interest since smooth muscle proliferation and abnormal lipid metabolism are proposed to play an important role in the pathogenesis of atherosclerotic plaque formation and in development of stenotic lesions following vascular injury by balloon angioplasty and coronary artery bypass grafting. On the basis of these observations, the antiproliferative actions of carvedilol have been explored in detail. In human cultured pulmonary artery vascular smooth muscle cells, carvedilol (0.1-10 microM) produced a concentration-dependent inhibition of the mitogenesis stimulated by platelet-derived growth factor, epidermal growth factor, thrombin, and serum, with IC50 values ranging from 0.3 to 2.0 microM. Carvedilol also produced a concentration-dependent inhibition of vascular smooth muscle cell migration induced by platelet-derived growth factor, with an IC50 value of 3 microM. The extensive neointimal formation that occurs following balloon angioplasty of rat carotid arteries was markedly attenuated by carvedilol (1 mg/kg, i.p.; twice daily starting 3 days before angioplasty and continuing until 14 days after angioplasty). Quantitative image analysis demonstrated that carvedilol reduced the neointimal growth following angioplasty by 84% without altering either medial or adventitial cross-sectional areas. These observations indicate that carvedilol may also be effective in the treatment of pathological disorders principally associated with abnormal vascular smooth muscle growth, such as atherosclerosis and acute vascular wall injury induced by angioplasty or coronary artery bypass grafting.
机译:卡维地洛是目前用于治疗高血压的心血管药物。最近的临床研究表明,它可有效治疗心绞痛和充血性心力衰竭。最近,已显示卡维地洛可减轻氧自由基引发的脂质过氧化作用,并抑制由多种生长因子诱导的血管平滑肌有丝分裂。这些发现是令人感兴趣的,因为提议平滑肌增殖和异常脂质代谢在动脉粥样硬化斑块形成的发病机理中以及在球囊血管成形术和冠状动脉旁路移植术引起的血管损伤后的狭窄病变的发展中起重要作用。基于这些观察,对卡维地洛的抗增殖作用进行了详细的研究。在人类培养的肺动脉血管平滑肌细胞中,卡维地洛(0.1-10 microM)对由血小板衍生的生长因子,表皮生长因子,凝血酶和血清刺激的促有丝分裂产生浓度依赖性抑制,IC50值范围为0.3至2.0微米卡维地洛还产生了血小板衍生生长因子诱导的血管平滑肌细胞迁移的浓度依赖性抑制作用,IC50值为3 microM。卡维地洛(1 mg / kg,腹腔内;每天两次从血管成形术前3天开始并持续到血管成形术后14天)显着减弱大鼠颈动脉球囊成形术后发生的广泛的新内膜形成。定量图像分析表明,卡维地洛可将血管成形术后的新内膜生长减少84%,而不会改变内侧或外膜的横截面积。这些观察结果表明卡维地洛也可能有效治疗主要与异常血管平滑肌生长有关的病理疾病,例如由血管成形术或冠状动脉搭桥术引起的动脉粥样硬化和急性血管壁损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号